Polyrizon

Polyrizon reports positive preclinical results for nasal allergy blocker

RA’ANANA, Israel - Polyrizon Ltd., a biotechnology company with a market capitalization of $11 million and currently rated as having WEAK financial health according to InvestingPro metrics, announced Friday that its PL-14 Allergy Blocker achieved encouraging preclinical results, demonstrating targeted deposition in the nasal vestibule, the first point of contact for airborne allergens.

The study, conducted with the University of Parma in Italy, showed that the company’s proprietary formulation achieved over 60% deposition in the nasal vestibule when administered under clinically relevant conditions. The evaluation used a validated silicone-based human nasal cast and fluorescein-labeled imaging to assess the spray deposition profile. Despite ongoing R&D efforts, the company maintains strong liquidity with a current ratio of 10.16 and more cash than debt on its balance sheet. Discover more financial insights with InvestingPro, which offers 8 additional key tips about Polyrizon’s financial position.

"We believe that the ability of our C&C platform to deliver a high concentration of hydrogel barrier to the vestibular region of the nose is a significant step forward," said Tomer Izraeli, CEO of Polyrizon, according to the company’s press release.

The PL-14 Allergy Blocker is part of Polyrizon’s Capture & Contain platform, designed to form a physical barrier that prevents allergens from triggering immune responses. The hydrogel formulation also maintained favorable sprayability and coverage under standard administration angles.

Professor Fabio Sonvico from the University of Parma’s Department of Food and Drug, who is also a member of Polyrizon’s Scientific Advisory Board, led the evaluation.

The biotechnology company, which specializes in intranasal products, plans to continue preclinical validation and advance toward clinical trials for its C&C platform.

The global allergen blocker market was valued at $0.14 billion in 2024 and is expected to reach $0.21 billion by 2033, according to Business Research Insights data cited in the company’s statement. While the market shows growth potential, Polyrizon’s stock has experienced significant volatility, declining over 99% in the past year. InvestingPro analysis indicates the stock is currently overvalued relative to its Fair Value estimate.

In other recent news, Polyrizon Ltd. announced it has regained compliance with Nasdaq listing requirements, allowing it to continue trading on the Nasdaq Capital Market. The company received formal confirmation from the Nasdaq Hearings Panel’s Hearings Advisor that it met the minimum bid price requirement. Additionally, Polyrizon revealed promising preclinical results for its PL-14 Allergy Blocker, which demonstrated over 60% deposition in the nasal vestibule during tests.